EGFR and non-small cell lung carcinoma: The APPROACH study (NCT04841811) will prospectively explore the efficacy and safety of induction aumolertinib therapy followed by different adjuvant therapy regimens guided by ctDNA dynamics in the MDT setting for unresectable stage III EGFR-mutated NSCLC.